With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.

The FDA said that PrEP – used to protect at-risk people such as an HIV-negative individual with ... which suggests it is expecting high demand for the injectable alternative.

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

PrEP became available in 2012, and so with it the freedom to have sex without fear of contracting HIV. But that doesn't mean everyone's on board. Those who are against PrEP believe that it ...

South Africa is home to one of the world's worst HIV/AIDS epidemics. At least 8.5 million people here are living with HIV - ...